New hope for aggressive brain tumors? early trial combines two targeted drugs
NCT ID NCT04160494
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a combination of two drugs—D2C7-IT and atezolizumab—in adults with a recurrent, aggressive type of brain cancer called grade IV malignant glioma. The main goal is to see if the combination is safe and what side effects it may cause. About 18 participants will receive the treatment at a specialized brain tumor center.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal fluid DNA test could personalize brain cancer therapy
- Experimental vaccine aims to rally immune system against recurrent brain cancer
- Immunotherapy drug nivolumab tested in young brain cancer patients
- Brain Tumor's hidden electrical signals could reveal its weaknesses
- Supercharged immune cells take on deadly brain tumors
- New MRI technique could spot brain tumor markers without a scalpel